You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK)向歐洲八國遞交利託那韋上市許可申請
阿思達克 03-01 17:06
歌禮制藥-B(01672.HK)公佈,通過歐洲代理商向歐洲八國(西班牙、葡萄牙、意大利、比利時、波蘭、瑞典、荷蘭和丹麥)遞交了利託那韋(100毫克薄膜衣片)上市許可申請。 除以上歐洲八國外,歌禮還完成向德國、法國、愛爾蘭和英國的利託那韋上市許可申請遞交。其他包括歐亞地區、北美和南美地區、非洲地區和亞太地區的利託那韋上市許可申請計劃在近期遞交。歌禮持續推進與國內公司和大型跨國製藥公司就利託那韋在中國和全球的商業化供應合作。 口服利託那韋片是針對病毒蛋白(酉每)的多種口服抗病毒藥物的藥代動力學增強劑及口服抗病毒藥物PAXLOVID(300毫克奈瑪特韋片+100毫克利託那韋片組合包裝)的組成之一。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account